Ionis Pharmaceuticals

IONS

Precision medicineBiotech & pharmaceuticals

$45.28vs prev close▲+1.98(+4.57%)

$42.6352W Range$86.74

6% from low

-10.37 (-18.63%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

2 buys

Concentrated buys

1M net buy

+$13.1M

≈ +267K shares

Portfolio Weight

0.23%

1M -0.03%p

Holding ETFs

1 ETFs

ARKG

Price Effect (Buy)

Shares increased, but price decline reduced portfolio weight.

Shares +47.0% · Market value +10.0% · Weight -0.03%p

Trade Intensity

Minor adjustment

Trade Log2-day BUY streak

Date	Action	ETF	Shares	Close	Est. total
26.09.21	BUY	ARKG	100,241	$44.90	$4.5M
26.09.14	BUY	ARKG	166,585	$51.44	$8.6M
26.08.19	BUY	ARKG	18,499	$60.80	$1.1M
26.08.18	BUY	ARKG	26,246	$59.62	$1.6M
26.08.17	BUY	ARKG	6,839	$58.63	$401.0K
26.07.14	BUY	ARKG	49,003	$54.93	$2.7M
26.07.13	BUY	ARKG	66,277	$56.75	$3.8M
26.07.10	BUY	ARKG	28,034	$58.25	$1.6M
26.07.09	BUY	ARKG	105,364	$64.27	$6.8M
26.03.25	SELL	ARKG	14,550	$72.70	$1.1M
26.03.13	SELL	ARKG	7,220	$71.19	$514.0K
26.03.12	SELL	ARKG	43,533	$72.34	$3.1M
26.02.27	SELL	ARKG	39,423	$81.15	$3.2M
26.01.12	SELL	ARKG	7,717	$81.66	$630.2K
26.01.06	SELL	ARKG	7,228	$81.49	$589.0K

09.21BUY

100,241

ARKGClose$44.90Est. total$4.5M

09.14BUY

166,585

ARKGClose$51.44Est. total$8.6M

08.19BUY

18,499

ARKGClose$60.80Est. total$1.1M

08.18BUY

26,246

ARKGClose$59.62Est. total$1.6M

08.17BUY

6,839

ARKGClose$58.63Est. total$401.0K

07.14BUY

49,003

ARKGClose$54.93Est. total$2.7M

07.13BUY

66,277

ARKGClose$56.75Est. total$3.8M

07.10BUY

28,034

ARKGClose$58.25Est. total$1.6M

07.09BUY

105,364

ARKGClose$64.27Est. total$6.8M

03.25SELL

14,550

ARKGClose$72.70Est. total$1.1M

03.13SELL

7,220

ARKGClose$71.19Est. total$514.0K

03.12SELL

43,533

ARKGClose$72.34Est. total$3.1M

02.27SELL

39,423

ARKGClose$81.15Est. total$3.2M

01.12SELL

7,717

ARKGClose$81.66Est. total$630.2K

01.06SELL

7,228

ARKGClose$81.49Est. total$589.0K

1 / 5

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

2 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

904,568

Portfolio Weight

0.23%

in ETF 1.61%

Est. Value

$39M

30D Net

+$13M

Ray DalioBridgewater Associates

Increased

67,706

Portfolio Weight

0.02%

Est. Value

$5M

vs Prev Quarter

+55% (44K→68K)

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Analyst Targets

avg.

$83.64

vs Current ▲ +84.7% upside

Current$45.28

Low ~ High$54.00 ~ $105.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

HC Wainwright & Co.

Buy

$100.00

+120.85%

$43.81

Maintain

2026-09-24

JP Morgan

Overweight

$70.00

+54.59%

$45.75

Maintain

2026-09-22

Guggenheim

Buy

$80.00

+76.68%

$47.25

Maintain

2026-09-15

Barclays

Overweight

$85.00

+87.72%

$56.02

Maintain

2026-09-09

Morgan Stanley

Overweight

$104.00

+129.68%

$56.71

Maintain

2026-09-08

1 / 4

Avg Target

$83.64

vs Current ▲ +84.7% upside

Buy

24 analysts

Strong Buy 9Buy 10Hold 5

Low $54.00

Current $45.28

High $105.00

Firm	Position	Target	Upside	Close	Action	Date
HC Wainwright & Co.	Buy	$100.00	+120.85%	$43.81	Maintain	26.09.24
JP Morgan	Overweight	$70.00	+54.59%	$45.75	Maintain	26.09.22
Guggenheim	Buy	$80.00	+76.68%	$47.25	Maintain	26.09.15
Barclays	Overweight	$85.00	+87.72%	$56.02	Maintain	26.09.09
Morgan Stanley	Overweight	$104.00	+129.68%	$56.71	Maintain	26.09.08

1 / 4

Price Information

Previous Close$43.30

Open$43.21

Day Range$43.12 - $45.72

52-Week Range$42.63 - $86.74

1-Year Change-35.85%

Trading Volume

Volume4,862,320

Avg Volume (3mo)3,409,584

Valuation

Market Cap7.5B

Book Value$2.65

Shares Outstanding166,184,322

Financials

Revenue (TTM)874.1M

Net Income-565,174,016

EPS$-3.48

EBITDA-579,484,992

Profitability

P/E Ratio-

P/B Ratio17.05

Return on Equity (ROE)-105.50%

Return on Assets (ROA)-12.42%

Profit Margin-64.66%

EV/EBITDA-13.13

Beta0.38

Dividend

Dividend Rate-

Dividend Yield0.00%

Technical

RSI(14)51.77

Company Overview

Ionis Pharmaceuticals is a commercial-stage biotechnology company specializing in RNA-targeted medicines. Their main products include treatments for rare genetic neurological diseases like spinal muscular atrophy (SMA), hereditary transthyretin-mediated amyloidosis (ATTRv-PN), and ALS, as well as conditions like familial chylomicronemia syndrome (FCS). Ionis holds a significant position in the market for developing innovative therapies for these unmet medical needs.

P/B

17.05

High valuation

ROE

-105.5%

Persistent loss

Beta

0.38

Low volatility

RSI(14)

51.8

Neutral

AI-generated summary. Not investment advice.

Ionis Pharmaceuticals

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks